• OPEN AN ACCOUNT
Indian Indices
Sensex
80,900.16 -1,369.62
( -1.66%)
Global Indices
Nasdaq
48,928.31 -164.26
(-0.33%)
Dow Jones
6,963.16 -26.85
(-0.38%)
Hang Seng
53,392.10 16.50
(0.03%)
Nikkei 225
10,214.90 43.14
(0.42%)
Forex
USD-INR
91.92 0.08
(0.09%)
EUR-INR
109.97 0.03
(0.03%)
GBP-INR
126.94 0.27
(0.21%)
JPY-INR
0.60 0.00
(0.00%)

EQUITY - MARKET SCREENER

Docmode Health Technologies Ltd
Industry :  Miscellaneous
BSE Code
ISIN Demat
Book Value()
79225
INE0OGG01015
26.5791651
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
DHTL
0
20.32
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

aavas financiers ltd
Fredun Pharma gains after launching new product
Oct 13,2025
The product, launched under Fredun's Freossi brand, is free from root vegetables, meat, and animal-derived ingredients, in line with Jain dietary principles. It is designed to support pet immunity, digestion, bone health, and energy.

Snacky Jain will be initially available in six cities through veterinary clinics, online platforms, and retail partners, with expansion planned for Ahmedabad, Pune, Bengaluru, and Delhi.

The product is manufactured at the company’s WHO-GMP-certified Palghar facility. Fredun said the launch strengthens its position in India's pet healthcare market, estimated at Rs 10,000 crore and growing at over 22% annually.

Fredun Pharmaceuticals, a healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. The company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

On a standalone basis, Fredun Pharmaceuticals' net profit rose 63.92% to Rs 6.77 crore while net sales rose 53.99% to Rs 119.40 crore in Q1 June 2025 over Q1 June 2024.